CEBP 09 AM Call for Abstracts w/deadline Cancer Health Disparities Conference 2009
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kresty, L. A.
Right arrow Articles by Hecht, S. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kresty, L. A.
Right arrow Articles by Hecht, S. S.

Cancer Epidemiology Biomarkers & Prevention, Vol 5, Issue 7 521-525, Copyright © 1996 by American Association for Cancer Research


ARTICLES

Metabolites of a tobacco-specific nitrosamine, 4-(methylnitrosamino)- 1-(3-pyridyl)-1-butanone (NNK), in the urine of smokeless tobacco users: relationship between urinary biomarkers and oral leukoplakia

LA Kresty, SG Carmella, A Borukhova, SA Akerkar, R Gopalakrishnan, RE Harris, GD Stoner and SS Hecht
Department of Preventive Medicine, Ohio State University, Columbus, USA.

Two metabolites of the carcinogenic tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone were quantified in the urine of smokeless tobacco users. The metabolites are 4-(methylnitrosamino) -1-(3-pyridyl)-1-butanol (NNAL) and [4-(methylnitrosamino)-1-(3-pyridyl) but-1-yl]-beta-O-D-glucosiduronic acid (NNAL-Gluc). The study population consisted of 47 male nonsmokers, of whom 23 were snuff dippers, 13 were tobacco chewers, 3 were users of both products, and 8 were nonusers. The levels of NNAL-Gluc in urine ranged from 0.14-30.3 pmol/mg creatinine with a mean +/- SD of 3.47 +/- 5.86, whereas the levels of NNAL ranged from 0.02-8.73 pmol/mg creatinine with a mean +/- SD of 0.92 +/- 1.59. The mean levels of NNAL-Gluc and NNAL were not significantly different from those measured in a previous study of smokers. The levels of NNAL-Gluc were significantly higher in snuff dippers than in tobacco chewers. The ratio of NNAL-Gluc:NNAL was higher in snuff dippers than in tobacco chewers or smokers. There was no indication of two phenotypes of the NNAL-Gluc:NNAL ratio in smokeless tobacco users, in contrast to previous observations in smokers. Of the 39 smokeless tobacco users in this study, 16 presented with oral leukoplakia. When the total levels of NNAL-Gluc, NNAL, or NNAL-Gluc + NNAL were divided into tertiles, there was a significant association between the presence of leukoplakia and increasing levels of these metabolites; a similar relationship was found between urinary cotinine and leukoplakia. The results of this study demonstrate that there is significant uptake of carcinogenic nitrosamines in smokeless tobacco users, and that such products are not harmless alternatives to cigarettes. Moreover, the urinary biomarkers NNAL-Gluc, NNAL, and cotinine were associated with the presence of leukoplakia, which provides biochemical support for the role of smokeless tobacco products as a cause of oral leukoplakia.


This article has been cited by other articles:


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
S. S. Hecht, S. G. Carmella, S. E. Murphy, W. T. Riley, C. Le, X. Luo, M. Mooney, and D. K. Hatsukami
Similar Exposure to a Tobacco-Specific Carcinogen in Smokeless Tobacco Users and Cigarette Smokers
Cancer Epidemiol. Biomarkers Prev., August 1, 2007; 16(8): 1567 - 1572.
[Abstract] [Full Text] [PDF]


Home page
aacredbookHome page
S. S. Hecht
Tobacco Carcinogen Biomarkers: Old and New
Am. Assoc. Cancer Res. Educ. Book, April 1, 2005; 2005(1): 85 - 88.
[Full Text] [PDF]


Home page
CarcinogenesisHome page
S. S. Hecht
Human urinary carcinogen metabolites: biomarkers for investigating tobacco and cancer
Carcinogenesis, June 1, 2002; 23(6): 907 - 922.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. S. Hecht, S. G. Carmella, M. Ye, K.-a. Le, J. A. Jensen, C. L. Zimmerman, and D. K. Hatsukami
Quantitation of Metabolites of 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone after Cessation of Smokeless Tobacco Use
Cancer Res., January 1, 2002; 62(1): 129 - 134.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
P. Upadhyaya, P. M.J. Kenney, J. B. Hochalter, M. Wang, and S. S. Hecht
Tumorigenicity and metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol enantiomers and metabolites in the A/J mouse
Carcinogenesis, August 1, 1999; 20(8): 1577 - 1582.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1996 by the American Association for Cancer Research.